Background: There is a lack of detailed population-based data for renal cell carcinoma (RCC). Objectives: The study aimed to examine the contemporary changes in the clinical picture and treatment of RCC. Methods: A total of 1,719 consecutive patients living in the Helsinki metropolitan area with a solid or cystic renal mass (Bosniak 3–4) ≥10 mm were identified. Data from medical records was evaluated for clinical characteristics and treatments in the periods I (2006–2008), II (2009–2011), III (2012–2014), and IV (2015–2016). Results: The proportions of patients with comorbidities (Charlson index ≥2) and frailty (Eastern Co-operative Oncology Group classification ≥2) increased significantly during the study period. The percentage of clinical stage I patients, cystic tumors and use of needle biopsies increased significantly. Use of observation increased from 9% (I) to 32% (IV; p < 0.001). First-line oncological treatments within 6 months were given to 47% of 262 patients with metastases and -cytoreductive nephrectomy (CN) was delivered to 54% of those patients. Conclusions: The size of renal tumors continued to decrease, while the percentage of patients with significant comorbidity or frailty increased. Active surveillance emerged as the initial strategy. Tyrosine kinase inhibitors with CN remained the primary option in patients with metastatic RCC.

Keywords:
Renal cell carcinoma, Renal tumor, Kidney neoplasms, Observation, Surveillance, Population-based
1.
Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK: Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst 2006; 98: 1331–1334.
2.
Nisen H, Jarvinen P, Fovaeus M, Guðmundsson E, Kromann-Andersen B, Ljungberg B, et al: Contemporary treatment of renal tumors: a questionnaire survey in the Nordic countries (the NORENCA-I study). Scand J Urol 2017; 51: 360–366.
3.
Volpe A, Cadeddu JA, Cestari A, Gill IS, Jewett MA, Joniau S, et al. Contemporary management of small renal masses. Eur Urol 2011; 60: 501–515.
4.
Jewett MA, Mattar K, Basiuk J, Morash CG, Pautler SE, Siemens DR, et al: Active surveillance of small renal masses: progression patterns of early stage kidney cancer. Eur Urol 2011; 60: 39–44.
5.
Smaldone MC, Kutikov A, Egleston BL, Canter DJ, Viterbo R, Chen DY, et al: Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis. Cancer 2012; 118: 997–1006.
6.
EAU Guideline on Renal Cell Cacinoma. 2017. from: https://uroweb.org/guidelines/renal-cell-carcinoma/ (cited January 17, 2018).
7.
Bex A, Albiges L, Ljungberg B, Bensalah K, Dabestani S, Giles RH, et al: Updated European association of urology guidelines for cytoreductive nephrectomy in patients with synchronous metastatic clear-cell renal cell carcinoma. Eur Urol 2018; 74: 805–809.
8.
Mehrazin R, Smaldone MC, Kutikov A, Li T, Tomaszewski JJ, Canter DJ, et al: Growth kinetics and short-term outcomes of cT1b and cT2 renal masses under active surveillance. J Urol 2014; 192: 659–664.
9.
Bosniak MA: The current radiological approach to renal cysts. Radiology 1986; 158: 1–10.
10.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228–247.
11.
Dindo D, Demartines N, Clavien PA: Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004; 240: 205–213.
12.
Srigley JR, Delahunt B, Eble JN, Egevad L, Epstein JI, Grignon D, et al: The International Society of Urological Pathology (ISUP) vancouver classification of renal neoplasia. Am J Surg Pathol 2013; 37: 1469–1489.
13.
Thorstenson A, Bergman M, Scherman-Plogell AH, Hosseinnia S, Ljungberg B, Adolfsson J, et al: Tumour characteristics and surgical treatment of renal cell carcinoma in Sweden 2005–2010: a population-based study from the national Swedish kidney cancer register. Scand J Urol 2014; 48: 231–238.
14.
Beisland C, Johannesen TB, Reisaeter LAR, Hjelle KM: Real-life use of diagnostic biopsies before treatment of kidney cancer: results from a Norwegian population-based study. Scand J Urol 2017: 1–7.
15.
Altekruse SF, Dickie L, Wu XC, Hsieh MC, Wu M, Lee R, et al: Clinical and prognostic factors for renal parenchymal, pelvis, and ureter cancers in SEER registries: collaborative stage data collection system, version 2. Cancer 2014; 120(suppl 23): 3826–3835.
16.
Patel HD, Johnson MH, Pierorazio PM, Sozio SM, Sharma R, Iyoha E, et al: Diagnostic accuracy and risks of biopsy in the diagnosis of a renal mass suspicious for localized renal cell carcinoma: systematic review of the literature. J Urol 2016; 195: 1340–1347.
17.
Kutikov A, Smaldone MC, Uzzo RG, Haifler M, Bratslavsky G, Leibovich BC: Renal mass biopsy: always, sometimes, or never? Eur Urol 2016; 70: 403–406.
18.
Leppert JT, Hanley J, Wagner TH, Chung BI, Srinivas S, Chertow GM, et al: Utilization of renal mass biopsy in patients with renal cell carcinoma. Urology 2014; 83: 774–779.
19.
Keegan KA, Schupp CW, Chamie K, Hellenthal NJ, Evans CP, Koppie TM: Histopathology of surgically treated renal cell carcinoma: survival differences by subtype and stage. J Urol 2012; 188: 391–397.
20.
National Cancer Institute Surveillance, Epidemi-ology and End Results Program: Cancer Stat Facts: Kidney and Renal Pelvis Cancer. 2018. https://seer.cancer.gov/ (cited accessed March 6, 2018).
21.
Mejean A, Ravaud A, Thezenas S, Colas S, Beauval JB, Bensalah K, et al: Sunitinib alone or after nephrectomy in metastatic clear-cell carcinoma. N Engl J Med 2018; 379: 417–427.
22.
de Groot S, Redekop WK, Sleijfer S, Oosterwijk E, Bex A, Kiemeney LA, et al: Survival in patients with primary metastatic renal cell carcinoma treated with sunitinib with or without previous cytoreductive nephrectomy: results from a population-based registry. Urology 2016; 95: 121–127.
23.
Conti SL, Thomas IC, Hagedorn JC, Chung BI, Chertow GM, Wagner TH, et al: Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era. Int J Cancer 2014; 134: 2245–2252.
24.
Bedke J, Stuhler V, Stenzl A, Brehmer B: Immunotherapy for kidney cancer: status quo and the future. Curr Opin Urol 2018; 28: 8–14.
25.
Dripps RD, Lamont A, Eckenhoff JE: The role of anesthesia in surgical mortality. JAMA 1961; 178: 261–266.
26.
Charlson M, Szatrowski TP, Peterson J, Gold J: Validation of a combined comorbidity index. J Clin Epidemiol 1994; 47: 1245–1251.
27.
Kutikov A, Egleston BL, Wong YN, Uzzo RG: Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram. J Clin Oncol 2010; 28: 311–317.
28.
Ethun CG, Bilen MA, Jani AB, Maithel SK, Ogan K, Master VA: Frailty and cancer: Implications for oncology surgery, medical oncology, and radiation oncology. CA Cancer J Clin 2017; 67: 362–377.
29.
Sand KE, Hjelle KM, Rogde AJ, Gudbrandsdottir G, Bostad L, Beisland C: Incidentally detected renal cell carcinomas are highly associated with comorbidity and mortality unrelated to renal cell carcinoma. Scand J Urol 2013; 47: 462–471.
30.
Hall DE, Arya S, Schmid KK, Carlson MA, Lavedan P, Bailey TL, et al: Association of a Frailty screening initiative with postoperative survival at 30, 180, and 365 days. JAMA Surg 2017; 152: 233–240.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.